LIBRETTO-432 Trial Results Significantly Improve Early Lung Cancer Prognosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 31 2026
0mins
Source: PRnewswire
- Clinical Trial Success: Eli Lilly's LIBRETTO-432 trial demonstrates that Retevmo (selpercatinib) as adjuvant therapy significantly improves event-free survival (EFS) in early-stage RET fusion-positive non-small cell lung cancer patients, reducing the risk of recurrence or death by 83%, thus providing a new treatment option for early lung cancer patients.
- Data Publication and Presentation: The trial results will be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting, highlighting the significance of this research in lung cancer treatment and potentially prompting changes in clinical practice.
- Patient Recruitment and Analysis: A total of 151 patients were enrolled in the trial, randomized to receive either Retevmo or placebo, and after a median follow-up of 24 months, the EFS rate was 94% in the Retevmo group compared to 70% in the placebo group, showcasing the significant efficacy of Retevmo.
- Safety and Tolerability: The safety profile of Retevmo aligns with previous studies, with the most common adverse events being elevated ALT and AST at 17% and 19%, respectively, which can be effectively managed through dose adjustments, ensuring patient safety during treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1160.950
Low
950.00
Averages
1192
High
1500
Current: 1160.950
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Weight-Loss Pill Approved in the UK
- Regulatory Approval: The UK's Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk's Wegovy weight-loss pill, providing over 10 million obese patients with a new needle-free treatment option, significantly enhancing Novo's competitive edge in the market.
- Market Potential: With obesity affecting approximately 30% of adults, equating to an estimated 13 to 14 million people, the approval of Wegovy is expected to drive demand for weight-loss medications and reshape the pharmaceutical landscape.
- Eligibility Criteria: The pill is approved for adults with a BMI of 30 or above, or those with a BMI between 27 and 30 with at least one related condition, and is anticipated to be available through private prescriptions within weeks, broadening patient access.
- Industry Impact: Wegovy contains the same active ingredient, semaglutide, as Novo's blockbuster injectable drugs, which is expected to accelerate the company's leadership in the weight-loss market while increasing competitive pressure on rivals like Eli Lilly.
See More
Pfizer's New Drug Intensifies Competition in Weight Loss Market
- Pfizer's Drug Introduction: Pfizer's weight loss drug berobenatide, requiring only monthly injections, is set to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound, potentially putting market pressure on both companies.
- Clinical Trial Results: The latest phase 2b trial showed an average weight loss of 15.9%, and while Novo Nordisk and Eli Lilly's drugs may perform better under clinical management, the convenience of berobenatide could attract more patients.
- Market Outlook Analysis: Morgan Stanley projects the weight loss drug market will reach $150 billion by 2035, and Pfizer's entry may weaken the pricing power of Novo Nordisk and Eli Lilly, impacting their future revenues.
- Long-term Strategic Impact: Pfizer plans to launch multiple weight loss drugs in the coming years, and although the short-term revenue contribution may be limited, the enhanced competitiveness poses a potential threat to shareholders of Novo Nordisk and Eli Lilly.
See More
Analysis of Three Dividend Growth Stocks
- Eli Lilly's Strong Growth: Eli Lilly reported Q1 revenue of $19.8 billion, a 56% year-over-year increase, with EPS soaring 156% to $8.55, driven by the success of its GLP-1 drug Mounjaro, and forecasts 2026 revenue between $82 billion and $85 billion, indicating robust market demand and future growth potential.
- Parker-Hannifin's Resilient Performance: Parker-Hannifin raised its dividend by 11% to $2 per share in April, marking its 70th consecutive year of increases, with a five-year dividend growth rate nearing 94%, while overall revenue grew 11% to $5.5 billion in Q3, showcasing its strong pricing power in global supply chains and clean technology infrastructure.
- Microsoft's Dual Growth in Revenue and Dividends: Microsoft reported Q3 revenue of $82.9 billion, an 18% year-over-year increase, with EPS rising 23% to $4.27, and a 10% dividend increase to $0.91 per quarter last September, reflecting its sustained growth in cloud computing and AI sectors.
- Investment Opportunities in Dividend Growth: These three companies have not only increased dividends by over 50% in the past five years but also maintain payout ratios below 27%, indicating their capacity for continued dividend increases, making them suitable for investors seeking stable income and capital appreciation.
See More
Pfizer Enters Weight Loss Drug Market with Berobenatide
- Drug Development Progress: Pfizer's weight loss drug berobenatide shows promise in its latest phase 2b trial, indicating potential for monthly injections with an average weight loss of 15.9% over 32 weeks, providing new hope for Pfizer in a competitive market.
- Increased Market Competition: With Pfizer entering the weight loss drug market, it will compete against giants like Novo Nordisk and Eli Lilly, which reported sales of $30 billion and $13.5 billion respectively, potentially undermining the pricing power of existing products.
- Diverse Clinical Trials: Pfizer is conducting multiple clinical trials for berobenatide, including 10 trials entering phase 3, indicating accelerated investment and strategic positioning in the weight loss drug sector.
- Long-Term Growth Potential: Pfizer anticipates a high single-digit revenue CAGR starting in 2029, although short-term performance may be impacted by declining COVID-19 drug sales, the potential of its weight loss drug business remains noteworthy.
See More
Eli Lilly Drives Dividend Growth with GLP-1 Products
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 products propelled its Q1 revenue to $19.8 billion, a 56% year-over-year increase, with EPS soaring 156% to $8.55, indicating robust market demand and profitability, while projected 2026 revenues of $82 to $85 billion further solidify its leadership in the pharmaceutical sector.
- Significant Dividend Growth: Eli Lilly recently raised its quarterly dividend by 15.3% to $1.73, achieving a 104% increase over the past five years, with a payout ratio of only 22.4%, demonstrating the company's capacity to consistently reward shareholders and enhance investor confidence.
- Parker-Hannifin's Stability: Parker-Hannifin increased its dividend by 11% to $2 per share in April, marking its 70th consecutive year of dividend increases, with a five-year dividend growth rate nearing 94%, showcasing its strong competitiveness and stable cash flow in the industrial technology sector.
- Microsoft's Continued Growth: Microsoft reported Q3 revenue of $82.9 billion, an 18% year-over-year increase, with EPS rising 23% to $4.27, and its cloud services achieving a remarkable 40% year-over-year growth, ensuring ongoing dividend increases and reinforcing its market position through a resilient subscription model.
See More
AbbVie Showcases New Data in Blood Cancer Portfolio
- Dividend Appeal: AbbVie's dividend yield exceeds 3%, significantly higher than the sub-2% yields of blue-chip healthcare stocks like Eli Lilly, Johnson & Johnson, and Amgen, indicating strong cash flow support that helps attract investors and bolster market confidence.
- EHA Conference Presentation: At the European Hematology Association Congress, AbbVie showcased 21 clinical data presentations on various blood cancers, enhancing its reputation in the treatment space and potentially facilitating future regulatory approvals and partnerships, thereby driving revenue growth.
- Diversified Revenue Streams: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, helping to reduce reliance on Humira and enhancing overall business resilience, ensuring sustained cash flow to support dividend payments.
- Ongoing R&D Investment: AbbVie is actively investing in expanding existing therapies and developing next-generation treatments, aiming to create new revenue sources through successful clinical trials, ensuring that oncology continues to be a growth driver and further solidifying its dividend-paying capacity.
See More
Novo Nordisk's Weight-Loss Pill Approved in the UK
- Regulatory Approval: The UK's Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk's Wegovy weight-loss pill, providing over 10 million obese patients with a new needle-free treatment option, significantly enhancing Novo's competitive edge in the market.
- Market Potential: With obesity affecting approximately 30% of adults, equating to an estimated 13 to 14 million people, the approval of Wegovy is expected to drive demand for weight-loss medications and reshape the pharmaceutical landscape.
- Eligibility Criteria: The pill is approved for adults with a BMI of 30 or above, or those with a BMI between 27 and 30 with at least one related condition, and is anticipated to be available through private prescriptions within weeks, broadening patient access.
- Industry Impact: Wegovy contains the same active ingredient, semaglutide, as Novo's blockbuster injectable drugs, which is expected to accelerate the company's leadership in the weight-loss market while increasing competitive pressure on rivals like Eli Lilly.
See More
Pfizer's New Drug Intensifies Competition in Weight Loss Market
- Pfizer's Drug Introduction: Pfizer's weight loss drug berobenatide, requiring only monthly injections, is set to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound, potentially putting market pressure on both companies.
- Clinical Trial Results: The latest phase 2b trial showed an average weight loss of 15.9%, and while Novo Nordisk and Eli Lilly's drugs may perform better under clinical management, the convenience of berobenatide could attract more patients.
- Market Outlook Analysis: Morgan Stanley projects the weight loss drug market will reach $150 billion by 2035, and Pfizer's entry may weaken the pricing power of Novo Nordisk and Eli Lilly, impacting their future revenues.
- Long-term Strategic Impact: Pfizer plans to launch multiple weight loss drugs in the coming years, and although the short-term revenue contribution may be limited, the enhanced competitiveness poses a potential threat to shareholders of Novo Nordisk and Eli Lilly.
See More
Analysis of Three Dividend Growth Stocks
- Eli Lilly's Strong Growth: Eli Lilly reported Q1 revenue of $19.8 billion, a 56% year-over-year increase, with EPS soaring 156% to $8.55, driven by the success of its GLP-1 drug Mounjaro, and forecasts 2026 revenue between $82 billion and $85 billion, indicating robust market demand and future growth potential.
- Parker-Hannifin's Resilient Performance: Parker-Hannifin raised its dividend by 11% to $2 per share in April, marking its 70th consecutive year of increases, with a five-year dividend growth rate nearing 94%, while overall revenue grew 11% to $5.5 billion in Q3, showcasing its strong pricing power in global supply chains and clean technology infrastructure.
- Microsoft's Dual Growth in Revenue and Dividends: Microsoft reported Q3 revenue of $82.9 billion, an 18% year-over-year increase, with EPS rising 23% to $4.27, and a 10% dividend increase to $0.91 per quarter last September, reflecting its sustained growth in cloud computing and AI sectors.
- Investment Opportunities in Dividend Growth: These three companies have not only increased dividends by over 50% in the past five years but also maintain payout ratios below 27%, indicating their capacity for continued dividend increases, making them suitable for investors seeking stable income and capital appreciation.
See More
Pfizer Enters Weight Loss Drug Market with Berobenatide
- Drug Development Progress: Pfizer's weight loss drug berobenatide shows promise in its latest phase 2b trial, indicating potential for monthly injections with an average weight loss of 15.9% over 32 weeks, providing new hope for Pfizer in a competitive market.
- Increased Market Competition: With Pfizer entering the weight loss drug market, it will compete against giants like Novo Nordisk and Eli Lilly, which reported sales of $30 billion and $13.5 billion respectively, potentially undermining the pricing power of existing products.
- Diverse Clinical Trials: Pfizer is conducting multiple clinical trials for berobenatide, including 10 trials entering phase 3, indicating accelerated investment and strategic positioning in the weight loss drug sector.
- Long-Term Growth Potential: Pfizer anticipates a high single-digit revenue CAGR starting in 2029, although short-term performance may be impacted by declining COVID-19 drug sales, the potential of its weight loss drug business remains noteworthy.
See More
Eli Lilly Drives Dividend Growth with GLP-1 Products
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 products propelled its Q1 revenue to $19.8 billion, a 56% year-over-year increase, with EPS soaring 156% to $8.55, indicating robust market demand and profitability, while projected 2026 revenues of $82 to $85 billion further solidify its leadership in the pharmaceutical sector.
- Significant Dividend Growth: Eli Lilly recently raised its quarterly dividend by 15.3% to $1.73, achieving a 104% increase over the past five years, with a payout ratio of only 22.4%, demonstrating the company's capacity to consistently reward shareholders and enhance investor confidence.
- Parker-Hannifin's Stability: Parker-Hannifin increased its dividend by 11% to $2 per share in April, marking its 70th consecutive year of dividend increases, with a five-year dividend growth rate nearing 94%, showcasing its strong competitiveness and stable cash flow in the industrial technology sector.
- Microsoft's Continued Growth: Microsoft reported Q3 revenue of $82.9 billion, an 18% year-over-year increase, with EPS rising 23% to $4.27, and its cloud services achieving a remarkable 40% year-over-year growth, ensuring ongoing dividend increases and reinforcing its market position through a resilient subscription model.
See More
AbbVie Showcases New Data in Blood Cancer Portfolio
- Dividend Appeal: AbbVie's dividend yield exceeds 3%, significantly higher than the sub-2% yields of blue-chip healthcare stocks like Eli Lilly, Johnson & Johnson, and Amgen, indicating strong cash flow support that helps attract investors and bolster market confidence.
- EHA Conference Presentation: At the European Hematology Association Congress, AbbVie showcased 21 clinical data presentations on various blood cancers, enhancing its reputation in the treatment space and potentially facilitating future regulatory approvals and partnerships, thereby driving revenue growth.
- Diversified Revenue Streams: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, helping to reduce reliance on Humira and enhancing overall business resilience, ensuring sustained cash flow to support dividend payments.
- Ongoing R&D Investment: AbbVie is actively investing in expanding existing therapies and developing next-generation treatments, aiming to create new revenue sources through successful clinical trials, ensuring that oncology continues to be a growth driver and further solidifying its dividend-paying capacity.
See More
